SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Oncolytics Biotech Inc.
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Gulo who wrote (18)9/1/2000 8:11:31 AM
From: blue_chip  Read Replies (1) of 103
 
NEWS RELEASE

Oncolytics Biotech Inc. Receives U.S. Patent Approval

Oncolytics Biotech Inc ONC
Shares issued 16,919,080 Aug 31 close $12.40
Fri 1 Sept 2000 News Release
Mr. Matt Coffey reports
The U.S. Patent and Trademark Office has issued patent 6,110,461 to
Oncolytics effective Aug. 29, 2000. The patent covers the pharmaceutical
use of the reovirus in the treatment of Ras-mediated cancers in mammals.
"The issuance of this patent provides us with our initial proprietary
position with respect to the development of reovirus as a therapeutic for
the treatment of cancer," said Dr. Matt Coffey, vice-president, product
development. "It is exciting and gratifying to receive approval for these
broad-based claims. It solidifies our platform by providing intellectual
property protection and removes an important element of risk in the
development and commercialization process."
WARNING: The company relies on litigation protection for "forward-looking"
statements.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News